StockData
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc. (OVID) stock

OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.26+0.04 (+1.80%)

Close on Nov 18, 2026Market cap $441.37MP/E –Yield –

Ovid Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Ovid Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$54.77M. For fiscal 2025 it was -$38.33M. The highest annual figure on record is $118.61M in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$38.33M–
FY2024Dec 31, 2024-$55.96M–
FY2023Dec 31, 2023-$45.78M–
FY2022Dec 31, 2022-$55.23M-146.6%
FY2021Dec 31, 2021$118.61M–
FY2020Dec 31, 2020-$51.58M–
FY2019Dec 31, 2019-$51.09M–
FY2018Dec 31, 2018-$45.56M–
FY2017Dec 31, 2017-$31.47M–
FY2016Dec 31, 2016-$17.80M–
FY2015Dec 31, 2015-$5.49M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$17.59M–
Q1 FY2026Mar 31, 2026-$13.90M–
Q4 FY2025Dec 31, 2025-$10.41M–
Q3 FY2025Sep 30, 2025-$12.87M–
Q2 FY2025Jun 30, 2025-$4.77M–
Q1 FY2025Mar 31, 2025-$10.28M–
Q4 FY2024Dec 31, 2024-$10.01M–
Q3 FY2024Sep 30, 2024-$15.01M–
Q2 FY2024Jun 30, 2024-$14.26M–
Q1 FY2024Mar 31, 2024-$16.69M–
Q4 FY2023Dec 31, 2023-$11.91M–
Q3 FY2023Sep 30, 2023-$10.05M–
Q2 FY2023Jun 30, 2023-$11.71M–
Q1 FY2023Mar 31, 2023-$12.11M–
Q4 FY2022Dec 31, 2022-$9.18M–
Q3 FY2022Sep 30, 2022-$12.68M–
Q2 FY2022Jun 30, 2022-$13.29M–
Q1 FY2022Mar 31, 2022-$20.09M-112.5%
Q4 FY2021Dec 31, 2021-$12.00M–
Q3 FY2021Sep 30, 2021-$10.87M–
Q2 FY2021Jun 30, 2021-$19.42M–
Q1 FY2021Mar 31, 2021$160.90M–
Q4 FY2020Dec 31, 2020-$14.51M–
Q3 FY2020Sep 30, 2020-$1.47M–
Q2 FY2020Jun 30, 2020-$17.19M–
Q1 FY2020Mar 31, 2020-$18.41M–
Q4 FY2019Dec 31, 2019-$16.89M–
Q3 FY2019Sep 30, 2019-$9.49M–
Q2 FY2019Jun 30, 2019-$11.84M–
Q1 FY2019Mar 31, 2019-$12.87M–
Q4 FY2018Dec 31, 2018-$10.97M–
Q3 FY2018Sep 30, 2018-$10.05M–
Q2 FY2018Jun 30, 2018-$11.62M–
Q1 FY2018Mar 31, 2018-$12.93M–
Q4 FY2017Dec 31, 2017-$9.01M–
Q3 FY2017Sep 30, 2017-$9.32M–
Q2 FY2017Jun 30, 2017-$5.99M–
Q1 FY2017Mar 31, 2017-$7.16M–
Q4 FY2016Dec 31, 2016-$5.71M–
Q3 FY2016Sep 30, 2016-$4.64M–

More Ovid Therapeutics figures

See a number that looks wrong?